# Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol

> **NCT00380276** · PHASE3 · TERMINATED · sponsor: **Myrexis Inc.** · enrollment: 1000 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** MPC-7869

## Key facts

- **NCT ID:** NCT00380276
- **Lead sponsor:** Myrexis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2008-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Why stopped:** Myriad has discontinued the development of Flurizan.
- **Last updated:** 2008-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00380276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00380276, "Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00380276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*